NeoPrediX

NeoPrediX AG is a company focused on developing intelligent algorithms and a cloud-based platform to support clinical decision-making for pregnant women and newborns. Their flagship product is the NeoPrediX B.1 algorithm, designed to accurately predict the dynamic progression of bilirubin levels in newborns over a 48-hour period.

Many newborns develop physiological jaundice after birth due to rising bilirubin levels, which is often harmless. However, to identify those at risk of bilirubin toxicity, bilirubin levels are measured multiple times after birth and before discharge. NeoPrediX B.1 utilizes the initial 1-2 bilirubin measurements to predict the individual bilirubin progression, enabling clinicians to provide personalized and optimized care.

In June 2022, NeoPrediX announced the successful completion of a prospective, multicenter observational study (Clinicaltrials.gov ID: NCT05121311) involving over 430 newborns to validate the predictive performance of the NeoPrediX B.1 algorithm. The results were consistent with previous studies, demonstrating the algorithm's ability to accurately forecast bilirubin changes over a defined period, aiding clinicians in personalized care.

NeoPrediX offers a cloud-based platform for hospitals to utilize the algorithm and generate individual prognoses for their patients. The first version of the platform is FDA-registered (510k exempt) and in use by healthcare providers in the US, with CE certification underway for a European launch expected in Q4 2022. Integration with electronic hospital information systems is in progress.